{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:35:40Z","timestamp":1793932540555,"version":"4.8.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Using Prader-Willi syndrome (PWS) as an example, this position statement focuses on supporting the development and evaluation of new treatments for rare neurodevelopmental disorders. As members of two patient advocacy organisations we have drawn on published research and the experience of participants, parents, paid care providers, and clinicians to make recommendations to improve the translational process from drug discovery to treatment approval and availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main text<\/jats:title>\n                    <jats:p>PWS is a rare complex genetically-determined neurodevelopmental condition. Severe hypotonia and failure to thrive are apparent at birth, followed by an atypical pattern of development associated with variable but characteristic physical and neuropsychiatric phenotypes. Like other neurodevelopmental conditions, atypical brain development results in intellectual and cognitive impairments. Relative growth and sex hormone deficiencies, the onset of hyperphagia in early childhood, and other phenotypic characteristics are a consequence of impaired hypothalamic function. Although growth hormone treatment for children with PWS has improved the phenotype of PWS, treatments for other features of the disorder are needed given their severe impact on the lives of people with PWS and their families. We identified factors that have delayed the development and evaluation of new treatments including: a limited understanding of causal mechanisms; additional measures required due to the participants\u2019 intellectual and cognitive impairments potentially impacting on consent, compliance, and requiring informant rather than participant-based outcome measures; high risk for co-morbidities; and recruitment from a small population; and over-restrictive inclusion\/exclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical trials can be performed in PWS but the associated complexities requires an understanding of the challenges and a more flexible approach to recruitment and trial design. The identification of biomarkers to screen new agents and for prediction of efficacy and outcome are warranted. Novel statistical methods for small numbers and\/or qualitative methodologies, may be necessary and appropriate. Robust and meaningful engagement of those living with PWS and their families, advocacy groups and expert clinicians is critical to the successful clinical trial completion. Given the example of the variable availability and affordability internationally of growth hormone to people with PWS, we express concern about the availability of new treatments globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04253-1","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:05:04Z","timestamp":1771059904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient advocacy group perspectives on treatment priorities and clinical trials for the rare neurodevelopmental condition, Prader-Willi syndrome"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-130X","authenticated-orcid":false,"given":"Anthony","family":"Holland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Strong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Garrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hoybye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maithe","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"4253_CR1","unstructured":"European Organisation for Rare Diseases (EURORDIS). Rare diseases: understanding this public health priority. 2005. Available at: eurordis.org\/IMG\/pdf\/princeps_document-EN.pdf. Accessed 20 Feb 2020."},{"issue":"4","key":"4253_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/1573396315666190625110748","volume":"15","author":"D Protic","year":"2019","unstructured":"Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. New targeted treatments for Fragile X syndrome. Curr Pediatr Rev. 2019;15(4):251\u201358. https:\/\/doi.org\/10.2174\/1573396315666190625110748.","journal-title":"Curr Pediatr Rev"},{"issue":"14","key":"4253_CR3","doi-asserted-by":"publisher","first-page":"1284035","DOI":"10.3389\/fphar.2023.1284035","volume":"16","author":"M Furqan","year":"2023","unstructured":"Furqan M. Trofinetide-a new chapter in Rett syndrome\u2019s treatment. Front Pharmacol. 2023;16(14):1284035. https:\/\/doi.org\/10.3389\/fphar.2023.1284035.","journal-title":"Front Pharmacol"},{"issue":"12","key":"4253_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/TCRM.S70068","volume":"2","author":"G Grugni","year":"2016","unstructured":"Grugni G, Sartorio A, Crin\u00f2 A. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016;2(12):873\u201381. https:\/\/doi.org\/10.2147\/TCRM.S70068.","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"4253_CR5","doi-asserted-by":"publisher","first-page":"e0221615","DOI":"10.1371\/journal.pone.0221615","volume":"14","author":"V Kimonis","year":"2019","unstructured":"Kimonis V, Surampalli A, Wencel M, Gold JA, Cowen NM. A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome. PLoS One. 2019;14(9):e0221615. https:\/\/doi.org\/10.1371\/journal.pone.0221615.","journal-title":"PLoS One"},{"key":"4253_CR6","doi-asserted-by":"publisher","first-page":"dgaf661","DOI":"10.1210\/clinem\/dgaf661","volume":"2","author":"JL Miller","year":"2026","unstructured":"Miller JL, Bridges N, Felner EI, Salehi P, Yanovski JA, Stevenson DA, et al. Diazoxide choline extended-release tablets in Prader-Willi syndrome: a randomized, double-blind, withdrawal period study. J Clin Endocrinol Metab. 2026;2:dgaf661. https:\/\/doi.org\/10.1210\/clinem\/dgaf661.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"4253_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1210\/clinem\/dgad014","volume":"108","author":"JL Miller","year":"2023","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. DESTINY PWS Investigators Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: a Double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2023;108(7):1676\u201385. https:\/\/doi.org\/10.1210\/clinem\/dgad014.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4253_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/oby.23928","volume":"32","author":"JL Miller","year":"2024","unstructured":"Miller JL, Gevers E, Bridges N, Yanovski JA, Salehi P, Obrynba KS, et al. C601\/C602 Investigators. Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label study. Obes (Silver Spring). 2024;32(2):252\u201361. https:\/\/doi.org\/10.1002\/oby.23928.","journal-title":"Obes (Silver Spring)"},{"key":"4253_CR9","unstructured":"Driscoll DJ, Miller JL, Schwartz S, et al. Prader-Willi syndrome. In: Adam MP, Mirzaa GM, Pagon RA, et al. In: GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1998. 1993-2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1330\/."},{"key":"4253_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-017-0673-6","volume":"12","author":"C Bar","year":"2017","unstructured":"Bar C, Diene G, Molinas C, et al. Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome. Orphanet J Rare Dis. 2017;12:118. https:\/\/doi.org\/10.1186\/s13023-017-0673-6.","journal-title":"Orphanet J Rare Dis"},{"key":"4253_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/jmg.38.11.792","volume":"38","author":"JE Whittington","year":"2001","unstructured":"Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, H B. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one health district. J Med Genet. 2001;38:792\u201398.","journal-title":"J Med Genet"},{"issue":"Supplement_1","key":"4253_CR12","doi-asserted-by":"publisher","first-page":"SUN","DOI":"10.1210\/jendso\/bvaa046.993","volume":"4","author":"MS McCandless","year":"2020","unstructured":"McCandless MS, Yin D, Yeh M, Czado S, Aghsaei S, Li JW, et al. SUN-604 U.S. Prevalence & mortality of Prader-Willi syndrome: a population-based study of medical claims. J Endocr Soc. 2020;4(Supplement_1):SUN-604. https:\/\/doi.org\/10.1210\/jendso\/bvaa046.993.","journal-title":"J The Endocr Soc"},{"issue":"1","key":"4253_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13023-019-1214-2","volume":"14","author":"DL Pacoricona Alfaro","year":"2019","unstructured":"Pacoricona Alfaro DL, Lemoine P, Ehlinger V, Molinas C, Diene G, Valette M, et al. Causes of death in Prader-Willi syndrome: lessons from 11 years\u2019 experience of a national reference center. Orphanet J Rare Dis. 2019;14(1):238. https:\/\/doi.org\/10.1186\/s13023-019-1214-2.","journal-title":"Orphanet J Rare Dis"},{"key":"4253_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.neubiorev.2016.09.013","volume":"72","author":"J Whittington","year":"2017","unstructured":"Whittington J, Holland A. Cognition in people with Prader-Willi syndrome: insights into genetic influences on cognitive and social development. Neurosci Biobehav Rev. 2017;72:153\u201367. https:\/\/doi.org\/10.1016\/j.neubiorev.2016.09.013.","journal-title":"Neurosci Biobehav Rev"},{"key":"4253_CR15","doi-asserted-by":"publisher","unstructured":"Schwartz L, Caix\u00e0s A, Dimitropoulos A, Dykens E, Duis J, Einfeld S, et al. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J Neurodev Disord. 2021;13(1):25. https:\/\/doi.org\/10.1186\/s11689-021-09373-2.","DOI":"10.1186\/s11689-021-09373-2"},{"issue":"5","key":"4253_CR16","doi-asserted-by":"publisher","first-page":"fcac229","DOI":"10.1093\/braincomms\/fcac229","volume":"4","author":"SSG Brown","year":"2022","unstructured":"Brown SSG, Manning KE, Fletcher P, Holland A. In vivo neuroimaging evidence of hypothalamic alteration in Prader-Willi syndrome. Brain Commun. 2022;4(5):fcac229. https:\/\/doi.org\/10.1093\/braincomms\/fcac229.","journal-title":"Brain Commun"},{"issue":"4","key":"4253_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S2213-8587(21)00002-4","volume":"9","author":"M Tauber","year":"2021","unstructured":"Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 2021;9(4):235\u201346. https:\/\/doi.org\/10.1016\/S2213-8587(21)00002-4.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4253_CR18","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1210\/jc.2008-0649","volume":"93","author":"AP Goldstone","year":"2008","unstructured":"Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelga AC, Tauber M. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4253_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1542\/peds.2010-2820","volume":"127","author":"SE McCandless","year":"2011","unstructured":"McCandless SE, Committee on Genetics. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195\u2013204. https:\/\/doi.org\/10.1542\/peds.2010-2820. Shawn E.","journal-title":"Pediatrics"},{"issue":"1","key":"4253_CR20","doi-asserted-by":"publisher","first-page":"e220373","DOI":"10.1530\/EC-22-0373","volume":"12","author":"C Poitou","year":"2022","unstructured":"Poitou C, Holland A, H\u00f6ybye C, de Graaff LCG, Bottius S, Otterlei B, et al. The transition from pediatric to adult care in individuals with Prader-Willi syndrome. Endocr Connect. 2022;12(1):e220373. https:\/\/doi.org\/10.1530\/EC-22-0373.","journal-title":"Endocr Connect"},{"issue":"2","key":"4253_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/jar.12950","volume":"35","author":"EM Dykens","year":"2022","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H. \u2018The cure for us is a lot of things\u2019: how young people with Prader-Willi syndrome view themselves and future clinical trials. J Appl Res Intellect Disabil. 2022;35(2):460\u201370. https:\/\/doi.org\/10.1111\/jar.12950.","journal-title":"J Appl Res Intellect Disabil"},{"issue":"12","key":"4253_CR22","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1080\/13696998.2018.1528980","volume":"21","author":"JH Tsai","year":"2018","unstructured":"Tsai JH, Scheimann AO, McCandless SE, Strong TV, Bridges JFP. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling. J Med Econ. 2018;21(12):1230\u201337. https:\/\/doi.org\/10.1080\/13696998.2018.1528980.","journal-title":"J Med Econ"},{"issue":"1","key":"4253_CR23","doi-asserted-by":"publisher","first-page":"104379","DOI":"10.1016\/j.ejmg.2021.104379","volume":"65","author":"SA Bellis","year":"2022","unstructured":"Bellis SA, Kuhn I, Adams S, Mullarkey L, Holland A. The consequences of hyperphagia in people with Prader-Willi syndrome: a systematic review of studies of morbidity and mortality. Eur J Med Genet. 2022;65(1):104379. https:\/\/doi.org\/10.1016\/j.ejmg.2021.104379.","journal-title":"Eur J Med Genet"},{"issue":"14","key":"4253_CR24","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.3390\/jcm11144033","volume":"11","author":"AGW Rosenberg","year":"2022","unstructured":"Rosenberg AGW, Wellink CM, Tellez Garcia JM, Pellikaan K, Van Abswoude DH, Davidse K, et al. Health problems in adults with Prader-Willi syndrome of different genetic subtypes: cohort study, meta-analysis and review of the literature. J Clin Med. 2022;11(14):4033. https:\/\/doi.org\/10.3390\/jcm11144033.","journal-title":"J Clin Med"},{"issue":"1","key":"4253_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13023-025-03787-0","volume":"20","author":"D Dempsey","year":"2025","unstructured":"Dempsey D, Hall M, Lanning B, Barron-Millar B, Huang M, Cowen N, et al. The burden of illness in Prader-Willi syndrome: a systematic literature review. Orphanet J Rare Dis. 2025;20(1):374. https:\/\/doi.org\/10.1186\/s13023-025-03787-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4253_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jir.13223","volume":"69","author":"K Micallef Pul\u00e8","year":"2025","unstructured":"Micallef Pul\u00e8 K, Hughes BM. Anxiety, depression and stress in parents and siblings of people who have Prader-Willi syndrome: morbidity prevalence and mitigating factors. J Intellect Disabil Res. 2025;69(5):417\u201327. https:\/\/doi.org\/10.1111\/jir.13223.","journal-title":"J Intellect Disabil Res"},{"issue":"3","key":"4253_CR27","doi-asserted-by":"publisher","first-page":"e0194655","DOI":"10.1371\/journal.pone.0194655","volume":"13","author":"N Kayadjanian","year":"2018","unstructured":"Kayadjanian N, Schwartz L, Farrar E, Comtois KA, Strong TV. High levels of caregiver burden in Prader-Willi syndrome. PLoS One. 2018;13(3):e0194655. https:\/\/doi.org\/10.1371\/journal.pone.0194655.","journal-title":"PLoS One"},{"issue":"3","key":"4253_CR28","doi-asserted-by":"publisher","first-page":"e0248739","DOI":"10.1371\/journal.pone.0248739","volume":"16","author":"N Kayadjanian","year":"2021","unstructured":"Kayadjanian N, Vrana-Diaz C, Bohonowych J, Strong TV, Morin J, Potvin D, et al. Characteristics and relationship between hyperphagia, anxiety, behavioral challenges and caregiver burden in Prader-Willi syndrome. PLoS One. 2021;16(3):e0248739. https:\/\/doi.org\/10.1371\/journal.pone.02487392.","journal-title":"PLoS One"},{"key":"4253_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10198-016-0788-z","volume":"17 Suppl 1","author":"J L\u00f3pez-Bastida","year":"2016","unstructured":"L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P, Kanavos P, et al. Social\/Economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.Eur. J Health Econ. 2016;17 Suppl 1:99\u2013108. https:\/\/doi.org\/10.1007\/s10198-016-0788-z.","journal-title":"J Health Econ"},{"issue":"7","key":"4253_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/DBP.0b013e3181ee3833","volume":"31","author":"DZ Wetmore","year":"2010","unstructured":"Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr. 2010;31(7):564\u201381. https:\/\/doi.org\/10.1097\/DBP.0b013e3181ee3833.","journal-title":"J Dev Behav Pediatr"},{"issue":"6","key":"4253_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/ng.158","volume":"40","author":"T Sahoo","year":"2008","unstructured":"Sahoo T, Del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C\/D box small nucleolar RNA cluster. Nat Genet. 2008;40(6):719\u201321. https:\/\/doi.org\/10.1038\/ng.158.","journal-title":"Nat Genet"},{"issue":"11","key":"4253_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/ejhg.2010.102","volume":"18","author":"AL Duker","year":"2010","unstructured":"Duker AL, Ballif BC, Bawle EV, Person RE, Mahadevan S, Alliman S, et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C\/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet. 2010;18(11):1196\u2013201. https:\/\/doi.org\/10.1038\/ejhg.2010.102.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"4253_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ejhg.2011.187","volume":"20","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Miller JL, Kuipers PJ, German JR, Beaudet AL, Sahoo T, et al. Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes. Eur J Hum Genet. 2012;20(3):283\u201390. https:\/\/doi.org\/10.1038\/ejhg.2011.187.","journal-title":"Eur J Hum Genet"},{"key":"4253_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/B978-0-12-820683-6.00029-4","volume":"181","author":"S Zahova","year":"2021","unstructured":"Zahova S, Isles AR. Animal models for Prader-Willi syndrome. Handb Clin Neurol. 2021;181:391\u2013404. https:\/\/doi.org\/10.1016\/B978-0-12-820683-6.00029-4.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"4253_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41398-022-02054-1","volume":"12","author":"F Althammer","year":"2022","unstructured":"Althammer F, Muscatelli F, Grinevich V, Schaaf CP. Oxytocin-based therapies for treatment of Prader-Willi and Schaaf-Yang syndromes: evidence, disappointments, and future research strategies. Transl Psychiatry. 2022;12(1):318. https:\/\/doi.org\/10.1038\/s41398-022-02054-1.","journal-title":"Transl Psychiatry"},{"issue":"9","key":"4253_CR36","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.stem.2021.04.006","volume":"28","author":"WK Huang","year":"2021","unstructured":"Huang WK, Wong SZH, Pather SR, Nguyen PTT, Zhang F, Zhang DY, et al. Generation of hypothalamic arcuate organoids from human induced pluripotent stem cells. Cell STEM Cell. 2021;28(9):1657\u201370.e10. https:\/\/doi.org\/10.1016\/j.stem.2021.04.006.","journal-title":"Cell STEM Cell"},{"key":"4253_CR37","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.dcn.2020.100764","volume":"42","author":"Y Fandakova","year":"2020","unstructured":"Fandakova Y, Hartley CA. Mechanisms of learning and plasticity in childhood and adolescence. Dev Cogn Neurosci. 2020;42:100764. https:\/\/doi.org\/10.1016\/j.dcn.2020.100764.","journal-title":"Dev Cogn Neurosci"},{"issue":"1","key":"4253_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-016-9167-4","volume":"8","author":"D Hessl","year":"2016","unstructured":"Hessl D, Sansone SM, Berry-Kravis E, Riley K, Widaman KF, Abbeduto L, et al. The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions. J Neurodev Disord. 2016;8(1):35. https:\/\/doi.org\/10.1186\/s11689-016-9167-4","journal-title":"J Neurodev Disord"},{"key":"4253_CR39","unstructured":"Mullen EM. Mullen scales of early learning (AGS ed.). American Guidance Service, Inc; 1995."},{"key":"4253_CR40","unstructured":"Sparrow SS, Cicchetti DV, Saulnier CA. Vineland Adaptive behavior scales. 3rd ed. Bloomington, MN: Pearson Assessment; 2016."},{"key":"4253_CR41","volume-title":"Manual for the Wechsler intelligence scale for children-revised","author":"D Wechsler","year":"1974","unstructured":"Wechsler D. Manual for the Wechsler intelligence scale for children-revised. Psychological Corporation; 1974."},{"key":"4253_CR42","volume-title":"WAIS-R : Wechsler adult intelligence scale-revised","author":"D Wechsler","year":"1981","unstructured":"Wechsler D. WAIS-R: Wechsler adult intelligence scale-revised. New York, N.Y: Psychological Corporation; 1981."},{"key":"4253_CR43","volume-title":"The social communication questionnaire","author":"M Rutter","year":"2003","unstructured":"Rutter M, Bailey A, Lord C. The social communication questionnaire. Western Psychological Services; 2003."},{"key":"4253_CR44","doi-asserted-by":"publisher","DOI":"10.1037\/t17260-000","volume-title":"Social Responsiveness Scale","author":"JN Constantino","year":"2003","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Social responsiveness scale [Database record]. APA PsycTests; 2003. https:\/\/doi.org\/10.1037\/t17260-000."},{"issue":"5","key":"4253_CR45","first-page":"492","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Deficiency. 1985;89(5):492\u2013502.","journal-title":"Am J Ment Deficiency"},{"issue":"1","key":"4253_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1176\/ajp.143.1.35","volume":"143","author":"SC Yudofsky","year":"1986","unstructured":"Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143(1):35\u201339.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"4253_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jval.2022.08.004","volume":"26","author":"SP Cotter","year":"2023","unstructured":"Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel SE. The Prader-Willi syndrome anxiousness and distress behaviors questionnaire: development and psychometric validation. Value Health. 2023;26(2):243\u201350.","journal-title":"Value Health"},{"key":"4253_CR48","doi-asserted-by":"publisher","DOI":"10.1037\/t17338-000","volume-title":"Repetitive behavior scale-revised (RBS-R)","author":"JW Bodfish","year":"2000","unstructured":"Bodfish JW, Symons FJ, Parker DE, Lewis MH. Repetitive behavior scale-revised (RBS-R) [Database record]. APA PsycTests; 2000. https:\/\/doi.org\/10.1037\/t17338-000."},{"issue":"1","key":"4253_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13023-024-03045-9","volume":"19","author":"EM Dykens","year":"2024","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H. The Prader-Willi syndrome Profile: validation of a new measure of behavioral and emotional problems in Prader-Willi syndrome. Orphanet J Rare Dis. 2024;19(1):83. https:\/\/doi.org\/10.1186\/s13023-024-03045-9.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4253_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1901\/jaba.1990.23-99","volume":"23","author":"BA Iwata","year":"1990","unstructured":"Iwata BA, Pace GM, Kissel RC, Nau PA, Farber JM. The Self-Injury Trauma (SIT) Scale: a method for quantifying surface tissue damage caused by self-injurious behavior. J Appl Behav Anal. 1990;23(1):99\u2013110. https:\/\/doi.org\/10.1901\/jaba.1990.23-99.","journal-title":"J Appl Behav Anal"},{"issue":"6","key":"4253_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep J Sleep Res Sleep Med. 1991;14(6):540\u201345. https:\/\/doi.org\/10.1093\/sleep\/14.6.540.","journal-title":"Sleep J Sleep Res Sleep Med"},{"issue":"1","key":"4253_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cpt.966","volume":"104","author":"ES Izmailova","year":"2018","unstructured":"Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: hype and hypothesis. Clin Pharmacol Ther. 2018;104(1):42\u201352. https:\/\/doi.org\/10.1002\/cpt.966.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4253_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11136-017-1681-7","volume":"27","author":"CB Forrest","year":"2018","unstructured":"Forrest CB, Devine J, Bevans KB, et al. Development and psychometric evaluation of the PROMIS pediatric life satisfaction item banks, child-report, and parent-proxy editions. Qual Life Res. 2018;27(1):217\u201334.","journal-title":"Qual Life Res"},{"issue":"1","key":"4253_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jcpp.12601","volume":"58","author":"EM Dykens","year":"2017","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H. Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome. J Child Psychol Psychiatry. 2017;58(1):64\u201374. https:\/\/doi.org\/10.1111\/jcpp.12601.","journal-title":"J Child Psychol Psychiatry"},{"issue":"1","key":"4253_CR55","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/ejendo\/lvad084","volume":"189","author":"DJ Trueba-Timmermans","year":"2023","unstructured":"Trueba-Timmermans DJ, Grootjen LN, Juriaans AF, Mahabier EF, Kerkhof GF, Rings EHHM, et al. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader-Willi syndrome. Eur J Endocrinol. 2023;189(1):132\u201339. https:\/\/doi.org\/10.1093\/ejendo\/lvad084.","journal-title":"Eur J Endocrinol"},{"key":"4253_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.trsl.2019.02","volume":"208","author":"Y Kim","year":"2019","unstructured":"Kim Y, Wang SE, Jiang YH. Epigenetic therapy of Prader-Willi syndrome. Transl Res. 2019;208:105\u201318. https:\/\/doi.org\/10.1016\/j.trsl.2019.02.","journal-title":"Transl Res"},{"issue":"6","key":"4253_CR57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5468\/ogs.2017.60.6.506","volume":"60","author":"EJ Kwon","year":"2017","unstructured":"Kwon EJ, Kim YJ. What is fetal programming?: a lifetime health is under the control of in utero health. Obstet Gynecol Sci. 2017, Nov;60(6):506\u201319. https:\/\/doi.org\/10.5468\/ogs.2017.60.6.506.","journal-title":"Obstet Gynecol Sci"},{"issue":"2","key":"4253_CR58","doi-asserted-by":"publisher","first-page":"e20162976","DOI":"10.1542\/peds.2016-2976","volume":"139","author":"M Tauber","year":"2017","unstructured":"Tauber M, Boulanouar K, Diene G, \u00c7abal-Berthoumieu S, Ehlinger V, Fichaux-Bourin P, et al. The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome. Pediatrics. 2017;139(2):e20162976. https:\/\/doi.org\/10.1542\/peds.2016-2976.","journal-title":"Pediatrics"},{"issue":"2","key":"4253_CR59","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1210\/jcem.80.2.7852523","volume":"80","author":"DF Swaab","year":"1995","unstructured":"Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995;80(2):573\u201379. https:\/\/doi.org\/10.1210\/jcem.80.2.7852523.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4253_CR60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biopsych.2014.11.010","volume":"78","author":"H Meziane","year":"2015","unstructured":"Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, et al. An early postnatal oxytocin treatment prevents social and learning deficits in adult mice deficient for Magel2, a gene involved in Prader-Willi syndrome and autism. Biol Psychiatry. 2015;78(2):85\u201394. https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.010.","journal-title":"Biol Psychiatry"},{"issue":"24","key":"4253_CR61","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1093\/hmg\/ddq424","volume":"19","author":"F Schaller","year":"2010","unstructured":"Schaller F, Watrin F, Sturny R, Massacrier A, Szepetowski P, Muscatelli F. A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Hum Mol Genet. 2010,;19(24):4895\u2013905. https:\/\/doi.org\/10.1093\/hmg\/ddq424.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"4253_CR62","doi-asserted-by":"publisher","first-page":"1026939","DOI":"10.3389\/fnins.2023.1026939","volume":"14","author":"V Gigliucci","year":"2023","unstructured":"Gigliucci V, Busnelli M, Santini F, Paolini C, Bertoni A, Schaller F, et al. Oxytocin receptors in the Magel2 mouse model of autism: specific region, age, sex and oxytocin treatment effects. Front Neurosci. 2023;14(17):1026939. https:\/\/doi.org\/10.3389\/fnins.2023.1026939.","journal-title":"Front Neurosci"},{"issue":"3","key":"4253_CR63","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/ijms24032150","volume":"24","author":"R Mahmoud","year":"2023","unstructured":"Mahmoud R, Kimonis V, Butler MG. Clinical trials in Prader-Willi syndrome: a review. Int J Mol Sci. 2023, Jan, 21;24(3):2150. https:\/\/doi.org\/10.3390\/ijms24032150.","journal-title":"Int J Mol Sci"},{"key":"4253_CR64","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11245-020-097724-z","volume":"40","author":"K Beaulieu","year":"2021","unstructured":"Beaulieu K, Blundell J. The psychobiology of hunger - a scientific perspective. Topoi. 2021;40:565\u201374. https:\/\/doi.org\/10.1007\/s11245-020-097724-z.","journal-title":"Topoi"},{"issue":"5","key":"4253_CR65","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ijo.2011.204","volume":"36","author":"LM Holsen","year":"2012","unstructured":"Holsen LM, Savage CR, Martin LE, Bruce AS, Lepping RJ, Ko E, et al. Importance of reward and prefrontal circuitry in hunger and satiety: Prader-Willi syndrome vs simple obesity. Int J Obes (Lond). 2012;36(5):638\u201347. https:\/\/doi.org\/10.1038\/ijo.2011.204.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"4253_CR66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0803128","volume":"30","author":"EC Hinton","year":"2006","unstructured":"Hinton EC, Holland AJ, Gellatly MS, Soni S, Patterson M, Ghatei MA, et al. Neural representations of hunger and satiety in Prader-Willi syndrome. Int J Obes (Lond). 2006;30(2):313\u201321. https:\/\/doi.org\/10.1038\/sj.ijo.0803128.","journal-title":"Int J Obes (Lond)"},{"key":"4253_CR67","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.brainres.2015.05.008","volume":"1620","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Wang J, Zhang G, Zhu Q, Cai W, Tian J, et al. The neurobiological drive for overeating implicated in Prader-Willi syndrome. Brain Res. 2015;1620:72\u201380. https:\/\/doi.org\/10.1016\/j.brainres.2015.05.008.","journal-title":"Brain Res"},{"issue":"7","key":"4253_CR68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nm0702-643","volume":"8","author":"DE Cummings","year":"2002","unstructured":"Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8(7):643\u201344. https:\/\/doi.org\/10.1038\/nm0702-643.","journal-title":"Nat Med"},{"issue":"12","key":"4253_CR69","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1210\/jc.2002-020871","volume":"87","author":"A DelParigi","year":"2002","unstructured":"DelParigi A, Tsch\u00f6p M, Heiman ML, Salbe AD, Vozarova B, Sell SM, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab. 2002;87(12):5461\u201364. https:\/\/doi.org\/10.1210\/jc.2002-020871.","journal-title":"J Clin Endocrinol Metab"},{"key":"4253_CR70","unstructured":"Millendo Therapeutics SAS. A Phase 2b\/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analogue, on food-related behaviors in patients with Prader-Willi syndrome. Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03790865. Accessed 1 Nov 2022."},{"issue":"1","key":"4253_CR71","doi-asserted-by":"publisher","first-page":"e0190849","DOI":"10.1371\/journal.pone.0190849","volume":"13","author":"S Allas","year":"2018","unstructured":"Allas S, Caix\u00e0s A, Poitou C, Coupaye M, Thuilleaux D, Lorenzini F, et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: a randomized placebo-controlled trial. PLoS One. 2018;13(1):e0190849. https:\/\/doi.org\/10.1371\/journal.pone.0190849.","journal-title":"PLoS One"},{"issue":"12","key":"4253_CR72","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/dom.13021","volume":"19","author":"SE McCandless","year":"2017","unstructured":"McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, et al. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(12):1751\u201361. https:\/\/doi.org\/10.1111\/dom.13021.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"4253_CR73","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1210\/clinem\/dgad015","volume":"108","author":"E Roof","year":"2023","unstructured":"Roof E, Deal CL, McCandless SE, Cowan RL, Miller JL, Hamilton JK, et al. Intranasal carbetocin reduces hyperphagia, anxiousness, and distress in Prader-Willi syndrome: CARE-PWS Phase 3 trial. J Clin Endocrinol Metab. 2023;108(7):1696\u2013708. https:\/\/doi.org\/10.1210\/clinem\/dgad015.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4253_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s11689-024-09536-x","volume":"16","author":"TV Strong","year":"2024","unstructured":"Strong TV, Miller JL, McCandless SE, Gevers E, Yanovski JA, Matesevac L, et al. Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study. J Neurodev Disord. 2024;16(1):22. https:\/\/doi.org\/10.1186\/s11689-024-09536-x.","journal-title":"J Neurodev Disord"},{"issue":"2","key":"4253_CR75","doi-asserted-by":"publisher","first-page":"238146832110394","DOI":"10.1177\/23814683211039457","volume":"6","author":"JH Tsai","year":"2021","unstructured":"Tsai JH, Crossnohere NL, Strong T, Bridges JFP. Measuring meaningful benefit-risk tradeoffs to promote patient-focused drug development in Prader-Willi syndrome: a discrete-choice experiment. MDM Policy Pract. 2021;6(2):23814683211039457. https:\/\/doi.org\/10.1177\/23814683211039457.","journal-title":"MDM Policy Pract"},{"issue":"2","key":"4253_CR76","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/jir.12010","volume":"58","author":"P Tunnicliffe","year":"2014","unstructured":"Tunnicliffe P, Woodcock K, Bull L, Oliver C, Penhallow J. Temper outbursts in Prader-Willi syndrome: causes, behavioural and emotional sequence and responses by carers. J Intellect Disabil Res. 2014;58(2):134\u201350. https:\/\/doi.org\/10.1111\/jir.12010.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"4253_CR77","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13023-022-02470-y","volume":"17","author":"M Deest","year":"2022","unstructured":"Deest M, Wieting J, Jakob MM, Deest-Gaubatz S, Groh A, Seifert J, et al. Aripiprazole treatment for temper outbursts in Prader-Willi syndrome. Orphanet J Rare Dis. 2022;17(1):324. https:\/\/doi.org\/10.1186\/s13023-022-02470-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4253_CR78","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajmg.a.62041","volume":"185","author":"M Deest","year":"2021","unstructured":"Deest M, Jakob MM, Seifert J, Bleich S, Frieling H, Eberlein C. Sertraline as a treatment option for temper outbursts in Prader-Willi syndrome. Am J Med Genet A. 2021;185(3):790\u201397. https:\/\/doi.org\/10.1002\/ajmg.a.62041.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"4253_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ajmg.b.33032","volume":"198","author":"D Singh","year":"2025","unstructured":"Singh D, Silver M, Jacob T. A randomized double-blind placebo-controlled trial of guanfacine extended release for aggression and self-injurious behavior associated with Prader-Willi syndrome. Am J Med Genet B Neuropsychiatr Genet. 2025;198(6):62\u201370. https:\/\/doi.org\/10.1002\/ajmg.b.33032.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"2","key":"4253_CR80","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jir.12203","volume":"60","author":"KE Manning","year":"2016","unstructured":"Manning KE, McAllister CJ, Ring HA, Finer N, Kelly CL, Sylvester KP, et al. Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation. J Intellect Disabil Res. 2016;60(2):149\u201355. https:\/\/doi.org\/10.1111\/jir.12203.","journal-title":"J Intellect Disabil Res"},{"issue":"12","key":"4253_CR81","doi-asserted-by":"publisher","first-page":"e0223750","DOI":"10.1371\/journal.pone.0223750","volume":"14","author":"KE Manning","year":"2019","unstructured":"Manning KE, Beresford-Webb JA, Aman LCS, Ring HA, Watson PC, Porges SW, et al. Transcutaneous vagus nerve stimulation (t-VNS): a novel effective treatment for temper outbursts in adults with Prader-Willi syndrome indicated by results from a non-blind study. PLoS One. 2019;14(12):e0223750. https:\/\/doi.org\/10.1371\/journal.pone.0223750.","journal-title":"PLoS One"},{"issue":"154","key":"4253_CR82","doi-asserted-by":"publisher","first-page":"104855","DOI":"10.1016\/j.ridd.2024.104855","volume":"13","author":"M Schmausser","year":"2024","unstructured":"Schmausser M, Holland A, Beresford-Webb J, Eglen SJ, Manning K, Aman L, et al. Effects of long-term transcutaneous auricular vagus nerve stimulation on circadian vagal activity in people with Prader-Willi syndrome: a case-series. Res Dev Disabil. 2024;13(154):104855. https:\/\/doi.org\/10.1016\/j.ridd.2024.104855.","journal-title":"Res Dev Disabil"},{"issue":"3","key":"4253_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10286-022-00909-7","volume":"33","author":"MG Butler","year":"2023","unstructured":"Butler MG, Victor AK, Reiter LT. Autonomic nervous system dysfunction in Prader-Willi syndrome. Clin Auton Res. 2023;33(3):281\u201386. https:\/\/doi.org\/10.1007\/s10286-022-00909-7.","journal-title":"Clin Auton Res"},{"key":"4253_CR84","doi-asserted-by":"publisher","first-page":"102955","DOI":"10.1016\/j.autneu.2022.102955","volume":"239","author":"A Holland","year":"2022","unstructured":"Holland A, Manning K. t-VNS to treat disorders of behaviour in Prader-Willi syndrome and in people with other neurodevelopmental conditions. Auton Neurosci. 2022;239:102955. https:\/\/doi.org\/10.1016\/j.autneu.2022.102955.","journal-title":"Auton Neurosci"},{"issue":"10","key":"4253_CR85","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ridd.2014.05.025","volume":"35","author":"SS Hall","year":"2014","unstructured":"Hall SS, Hustyi KM, Chui C, Hammond JL. Experimental functional analysis of severe skin-picking behavior in Prader-Willi syndrome. Res Dev Disabil. 2014;35(10):2284\u201392. https:\/\/doi.org\/10.1016\/j.ridd.2014.05.025.","journal-title":"Res Dev Disabil"},{"issue":"2","key":"4253_CR86","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S1461145702002833","volume":"5","author":"NA Shapira","year":"2002","unstructured":"Shapira NA, Lessig MC, Murphy TK, Driscoll DJ, Goodman WK. Topiramate attenuates self-injurious behaviour in Prader-Willi syndrome. Int J Neuropsychopharmacol. 2002;5(2):141\u201345. https:\/\/doi.org\/10.1017\/S1461145702002833.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"4253_CR87","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/ajmg.a.62589","volume":"188","author":"J Wieting","year":"2022","unstructured":"Wieting J, Deest M, Bleich S, Frieling H, Eberlein C. N-Acetylcysteine provides limited efficacy as treatment option for skin picking in Prader-Willi syndrome. Am J Med Genet A. 2022;188(3):828\u201335. https:\/\/doi.org\/10.1002\/ajmg.a.62589","journal-title":"Am J Med Genet A"},{"issue":"2","key":"4253_CR88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/s0887-8994(02)00490-3","volume":"28","author":"SA Smathers","year":"2003","unstructured":"Smathers SA, Wilson JG, Nigro MA. Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol. 2003;28(2):130\u201333. https:\/\/doi.org\/10.1016\/s0887-8994(02)00490-3.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"4253_CR89","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.5664\/jcsm.9938","volume":"18","author":"J Duis","year":"2022","unstructured":"Duis J, Pullen LC, Picone M, Friedman N, Hawkins S, Sannar E, et al. Diagnosis and management of sleep disorders in Prader-Willi syndrome. J Clin Sleep Med. 2022;18(6):1687\u201396. https:\/\/doi.org\/10.5664\/jcsm.9938.","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"4253_CR90","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.5664\/jcsm.11800","volume":"21","author":"A Revana","year":"2025","unstructured":"Revana A, Bhattacharjee R, Miller JL, et al. A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome. J Clin Sleep Med. 2025;21(11):1893\u2013902.","journal-title":"J Clin Sleep Med"},{"key":"4253_CR91","doi-asserted-by":"publisher","first-page":"103820","DOI":"10.1016\/j.ridd.2020.103820","volume":"108","author":"A Dimitropoulos","year":"2021","unstructured":"Dimitropoulos A, Zyga O, Doernberg E, Russ SW. Show me what happens next: preliminary efficacy of a remote play-based intervention for children with Prader-Willi syndrome. Res Dev Disabil. 2021;108:103820. https:\/\/doi.org\/10.1016\/j.ridd.2020.103820.","journal-title":"Res Dev Disabil"},{"issue":"1","key":"4253_CR92","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13023-024-03035-x","volume":"19","author":"BM Hughes","year":"2024","unstructured":"Hughes BM, Holland A, H\u00f6debeck-Stuntebeck N, Garrick L, Goldstone AP, Lister M, et al. Body weight, behaviours of concern, and social contact in adults and adolescents with Prader-Willi syndrome in full-time care services: findings from pooled international archival data. Orphanet J Rare Dis. 2024;19(1):48. https:\/\/doi.org\/10.1186\/s13023-024-03035-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4253_CR93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.31486\/toj.19.0079","volume":"20","author":"BG Gordon","year":"2020","unstructured":"Gordon BG. Vulnerability in research: basic ethical concepts and general approach to review. Ochsner J. 2020;20(1):34\u201338. https:\/\/doi.org\/10.31486\/toj.19.0079.","journal-title":"Ochsner J"},{"key":"4253_CR94","doi-asserted-by":"crossref","unstructured":"Dykens EM, Roof E, Hunt-Hawkins H, Strong TV. Validation of the food safe zone questionnaire for families of individuals with Prader-Willi syndrome. J Neurodev Disord. 2024;17:6.","DOI":"10.1101\/2024.01.26.24301844"},{"key":"4253_CR95","doi-asserted-by":"publisher","first-page":"A25","DOI":"10.1016\/j.jval.2015.03.154","volume":"18","author":"S Fehnel","year":"2015","unstructured":"Fehnel S, Brown M, Nelson L, Chen A, Roof E, Kim DD, et al. Development of the hyperphagia questionnaire for use in Prader-Willi syndrome clinical trials. Value Health. 2015;18:A25\u201325. https:\/\/doi.org\/10.1016\/j.jval.2015.03.154.","journal-title":"Value Health"},{"issue":"2","key":"4253_CR96","doi-asserted-by":"publisher","first-page":"e70053","DOI":"10.1111\/jar.70053","volume":"38","author":"L Schwartz","year":"2025","unstructured":"Schwartz L, Vrana-Diaz CJ, Bohonowych JE, Matesevac L, Strong TV. Life satisfaction, global health and mood in Prader-Willi syndrome: use of PROMIS and the Glasgow depression scale. J Appl Res Intell Disabil. 2025;38(2):e70053.","journal-title":"J Appl Res Intell Disabil"},{"issue":"4","key":"4253_CR97","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1352\/1934-9556-50.4.352","volume":"50","author":"GT Fujiura","year":"2012","unstructured":"Fujiura GT. RRTC Expert Panel on Health Measurement Self-reported health of people with intellectual disability. Intellect Dev Disabil. 2012;50(4):352\u201369. https:\/\/doi.org\/10.1352\/1934-9556-50.4.352.","journal-title":"Intellect Dev Disabil"},{"issue":"5","key":"4253_CR98","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/jar.12452","volume":"31","author":"HM Scott","year":"2018","unstructured":"Scott HM, Havercamp SM. Comparisons of self and proxy report on health-related factors in people with intellectual disability. J Appl Res Intellect Disabil. 2018;31(5):927\u201336. https:\/\/doi.org\/10.1111\/jar.12452.","journal-title":"J Appl Res Intellect Disabil"},{"issue":"7","key":"4253_CR99","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/oby.2007.216","volume":"15","author":"EM Dykens","year":"2007","unstructured":"Dykens EM, Maxwell MA, Pantino E, Kossler R, Roof E. Assessment of hyperphagia in Prader-Willi syndrome. Obes (Silver Spring). 2007;15(7):1816\u201326. https:\/\/doi.org\/10.1038\/oby.2007.216.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"4253_CR100","doi-asserted-by":"publisher","first-page":"20573","DOI":"10.1038\/s41598-023-48024-5","volume":"13","author":"L Matesevac","year":"2023","unstructured":"Matesevac L, Vrana-Diaz CJ, Bohonowych JE, Schwartz L, Strong TV. Analysis of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores in typically developing individuals and those with Prader-Willi syndrome. Sci Rep. 2023;13(1):20573. https:\/\/doi.org\/10.1038\/s41598-023-48024-5.","journal-title":"Sci Rep"},{"key":"4253_CR101","doi-asserted-by":"publisher","first-page":"030","DOI":"10.23937\/2643-4571\/1710030","volume":"4","author":"M Leffler","year":"2021","unstructured":"Leffler M, Elder SJ, Bolding S, Hefner M, Miller JL, et al. A qualitative methodology to support the evaluation of novel treatments for hyperphagia in people with Prader-Willi syndrome. Int J Rare Dis Disord. 2021;4:030. https:\/\/doi.org\/10.23937\/2643-4571\/1710030.","journal-title":"Int J Rare Dis Disord"},{"key":"4253_CR102","doi-asserted-by":"publisher","first-page":"117362","DOI":"10.1016\/j.eswa.2022.117362","volume":"202","author":"CV Anikwe","year":"2022","unstructured":"Anikwe CV, Nweke HF, Ikegwu AC, Egwuonwu CA, Onu FU, Alo UR, et al. Mobile and wearable sensors for data-driven health monitoring system: state-of-the-art and future prospect. Expert Syst Appl. 2022;202:117362. https:\/\/doi.org\/10.1016\/j.eswa.2022.117362.","journal-title":"Expert Syst Appl"},{"key":"4253_CR103","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrd.2017.70","volume":"16","author":"L Martin","year":"2017","unstructured":"Martin L, Hutchens M, Hawkins C, et al. How much do clinical trials cost? Nat Rev Drug Discov. 2017;16:381\u201382. https:\/\/doi.org\/10.1038\/nrd.2017.70.","journal-title":"Nat Rev Drug Discov"},{"key":"4253_CR104","doi-asserted-by":"publisher","unstructured":"Nisar S, Haris M. Neuroimaging genetics approaches to identify new biomarkers for the early diagnosis of autism spectrum disorder. Mol Psychiatry. 2023;28(12):4995\u20135008. https:\/\/doi.org\/10.1038\/s41380-023-02060-9. Erratum in: Mol Psychiatry. 2023;28(12):5009\u20135010. doi 10.1038\/s41380-023-02115-x.","DOI":"10.1038\/s41380-023-02060-9"},{"issue":"125","key":"4253_CR105","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.appet.2018.02.008","volume":"1","author":"E Robinson","year":"2018","unstructured":"Robinson E, Bevelander KE, Field M, Jones A. Methodological and reporting quality in laboratory studies of human eating behavior. Appetite. 2018;1(125):486\u201391. https:\/\/doi.org\/10.1016\/j.appet.2018.02.008.","journal-title":"Appetite"},{"key":"4253_CR106","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.eclinm.2023.101882","volume":"58","author":"M Chakhtoura","year":"2023","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101882.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"4253_CR107","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000011597","volume":"96","author":"AR M\u00fcller","year":"2021","unstructured":"M\u00fcller AR, Brands MMMG, van de Ven PM, Roes KCB, Cornel MC, van Karnebeek CDM, et al. Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: the power of 1. Neurology. 2021;96(11):529\u201340. https:\/\/doi.org\/10.1212\/WNL.0000000000011597.","journal-title":"Neurology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04253-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04253-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04253-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:16:09Z","timestamp":1781633769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04253-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4253"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04253-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors approved the final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors are all associated with either the International PWS Organisation or the Foundation for PW Research as staff, trustees, or members of Scientific Boards. Some are also parents of children with PWS (LG,TS,MH,LS). In these various capacities they are committed to advancing the welfare of people with PWS and that of their families.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}